Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVIR NASDAQ:IRD NASDAQ:NGNE NASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$3.36-3.2%$3.56$2.45▼$4.14$266.64M0.25346,397 shs161,155 shsIRDOpus Genetics$1.22+2.5%$1.10$0.65▼$1.75$73.09M0.01188,606 shs162,369 shsNGNENeurogene$18.48-1.9%$20.38$6.88▼$74.49$263.75M1.69111,648 shs94,969 shsTNXPTonix Pharmaceuticals$29.63-3.8%$41.25$6.76▼$130.00$259.73M1.72.00 million shs667,083 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals0.00%-8.20%-7.69%+12.75%-11.58%IRDOpus Genetics0.00%+6.09%+9.91%+21.60%+121,999,900.00%NGNENeurogene0.00%-7.55%-15.11%+7.38%-48.31%TNXPTonix Pharmaceuticals0.00%-21.99%-21.36%-25.55%-1.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVIRAtea Pharmaceuticals2.4187 of 5 stars3.30.00.00.03.32.51.3IRDOpus Genetics2.0981 of 5 stars3.50.00.00.03.50.00.6NGNENeurogene1.9837 of 5 stars3.40.00.00.02.31.71.3TNXPTonix Pharmaceuticals2.9109 of 5 stars3.52.00.00.02.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.0078.57% UpsideIRDOpus Genetics 3.00Buy$7.33501.09% UpsideNGNENeurogene 2.75Moderate Buy$46.17149.82% UpsideTNXPTonix Pharmaceuticals 3.00Buy$70.00136.25% UpsideCurrent Analyst Ratings BreakdownLatest IRD, AVIR, TNXP, and NGNE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025IRDOpus GeneticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/17/2025NGNENeurogeneCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.006/12/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$22.00 ➝ $26.006/3/2025TNXPTonix PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVIRAtea PharmaceuticalsN/AN/AN/AN/A$4.59 per shareN/AIRDOpus Genetics$15.42M4.74N/AN/A$0.29 per share4.21NGNENeurogene$930K283.56N/AN/A$19.15 per share0.97TNXPTonix Pharmaceuticals$10.09M25.75N/AN/A$19.17 per share1.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVIRAtea Pharmaceuticals-$168.38M-$1.61N/AN/AN/AN/A-32.55%-30.47%11/6/2025 (Estimated)IRDOpus Genetics-$57.53M-$1.92N/AN/AN/A-377.89%-384.33%-148.90%11/11/2025 (Estimated)NGNENeurogene-$75.14M-$4.31N/AN/AN/AN/A-33.33%-30.34%11/17/2025 (Estimated)TNXPTonix Pharmaceuticals-$130.04M-$39.47N/AN/AN/A-828.22%-57.93%-51.04%11/11/2025 (Estimated)Latest IRD, AVIR, TNXP, and NGNE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025IRDOpus Genetics-$0.25-$0.12+$0.13-$0.12$4.27 million$2.88 million8/11/2025Q2 2025NGNENeurogene-$1.15-$1.05+$0.10-$1.05N/AN/A8/11/2025Q1 2025TNXPTonix Pharmaceuticals-$3.10-$3.86-$0.76-$3.86$2.60 million$2.00 million8/7/2025Q2 2025AVIRAtea Pharmaceuticals-$0.46-$0.44+$0.02-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVIRAtea PharmaceuticalsN/A19.1719.17IRDOpus Genetics0.061.901.90NGNENeurogeneN/A18.0718.07TNXPTonix PharmaceuticalsN/A7.537.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVIRAtea Pharmaceuticals86.67%IRDOpus Genetics14.97%NGNENeurogene52.37%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipAVIRAtea Pharmaceuticals18.10%IRDOpus Genetics6.60%NGNENeurogene11.64%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVIRAtea Pharmaceuticals7079.36 million64.99 millionOptionableIRDOpus Genetics1459.91 million55.95 millionN/ANGNENeurogene9014.27 million12.61 millionOptionableTNXPTonix Pharmaceuticals508.77 million8.76 millionNot OptionableIRD, AVIR, TNXP, and NGNE HeadlinesRecent News About These CompaniesTonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025August 28 at 7:00 AM | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Cross Above 200-Day Moving Average - Time to Sell?August 28 at 3:33 AM | marketbeat.comCarolyn Taylor Buys 418 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) StockAugust 22, 2025 | insidertrades.comSA analyst upgrades/downgrades: HD, AAPL, TMUS, TNXPAugust 20, 2025 | msn.comTonix Pharma Announces FDA Approval of TonmyaAugust 19, 2025 | msn.comTonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)August 19, 2025 | seekingalpha.comTonix Pharmaceuticals Reports Q2 2025 Financial ResultsAugust 19, 2025 | msn.comFDA Approves New Fibromyalgia Drug, But Tonix Shares SlideAugust 18, 2025 | msn.comTonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 YearsAugust 18, 2025 | finance.yahoo.comTonix Pharmaceuticals (TNXP) Faces Volatility Despite FDA ApprovalAugust 18, 2025 | gurufocus.comFDA Approves New Fibromyalgia Drug, Tonix Shares ClimbAugust 18, 2025 | msn.comThis Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’August 18, 2025 | msn.comTonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Stock Holdings Reduced by Virtu Financial LLCAugust 18, 2025 | marketbeat.comNoble Financial Has Pessimistic Outlook of TNXP Q3 EarningsAugust 17, 2025 | marketbeat.comFDA approves first new fibromyalgia treatment in over 15 yearsAugust 16, 2025 | thepharmaletter.comTTonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up - Time to Buy?August 16, 2025 | marketbeat.comTonix Secures Fibromyalgia Approval - What Investors Should KnowAugust 16, 2025 | seekingalpha.comTonix Pharma Gains FDA Approval for TonmyaAugust 16, 2025 | msn.comTonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of FibromyalgiaAugust 15, 2025 | manilatimes.netMTonix Pharmaceuticals jumps 17% to $60.13 after FDA approval of TonmyaAugust 15, 2025 | msn.comTonix Pharmaceuticals stock halted ahead of FDA approval newsAugust 15, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIRD, AVIR, TNXP, and NGNE Company DescriptionsAtea Pharmaceuticals NASDAQ:AVIR$3.36 -0.11 (-3.17%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.36 +0.01 (+0.15%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Opus Genetics NASDAQ:IRD$1.22 +0.03 (+2.52%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.26 +0.04 (+3.28%) As of 08/29/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.Neurogene NASDAQ:NGNE$18.48 -0.36 (-1.91%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$18.47 -0.01 (-0.05%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Tonix Pharmaceuticals NASDAQ:TNXP$29.63 -1.18 (-3.83%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$29.28 -0.36 (-1.20%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
